Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer

Observational Study - Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Tubular Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00947102

Acronym

GEMSTHER

Enrollment

Unknown

Registered

2009-07-27

Start date

2009-02-28

Completion date

2011-12-31

Last updated

2010-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Tubular Adenocarcinoma

Keywords

pancreatic tubular adenocarcinoma, gemcitabine, gene expression, immunological status, serological status, pancreatic tubular adenocarcinoma adjuvant setting

Brief summary

Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.

Interventions

OTHERObservation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 85 Years

Healthy volunteers

Inclusion criteria

* ECOG performance status 0-2 at the time of inclusion * Following R0 or R1 pancreatic tubular adenocarcinoma resection

Exclusion criteria

* Pregnancy * Serious comorbidity

Countries

Slovenia

Contacts

Primary ContactBorut Stabuc, MD, PhD

borut.stabuc@kclj.si+386 1 522 22 10

Backup ContactLojze Smid, MD

lojze.smid.jr@mf.uni-lj.si

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026